Skip to main content

Table 1 Fecal samples’ demographic, clinical, and technical details

From: Multi-cohort analysis of colorectal cancer metagenome identified altered bacteria across populations and universal bacterial markers

Cohort

Factor

Control

CRC

P value

Sample collection

Sequencing platform

Cohort C1 (American, 2016)

Sample size

52

48

NA

Prior to surgery and treatment

Sequencing Platform: Illumina Hiseq 2000/2500; Sequencing Target Depth: 5GB; read length: 100 bp

Age

61.23(11.03)

60.96(13.56)

0.913

Gender

Male:37; Female:15

Male:35; Female:13

1

BMI

25.35(4.27)

24.90(4.29)

0.601

Cohort C2 (Austrian, 2014)

Sample size

63

46

NA

Not available

Age

67.1(6.37)

67.1(10.91)

0.999

Gender

Male:37; Female:26

Male:28; Female:18

0.978

BMI

27.57(3.78)

26.50(3.53)

0.132

Cohort C3 (Chinese, 2015)

Sample size

92

73

NA

No antibiotics and no invasive medical intervention for 3 months; no vegetarian diet; no history of cancer or inflammatory disease of intestine

Age

58.51(7.55)

65.90(10.61)

< 0.0001

Gender

Male:51; Female:41

Male:47; Female:26

0.316

BMI

23.87(3.31)

24.07(3.18)

0.697

Cohort C4 (German and French, 2014)

Sample size

64

88

NA

No previous colon or rectal surgery, colorectal cancer, inflammatory, or infectious injuries of the intestine; no need for need for emergency colonoscopy

Age

58.75(12.96)

68.44(12.22)

0.007

Gender

Male:32; Female:32

Male:53; Female:35

0.276

BMI

24.72(3.19)

25.89(4.29)

0.056